



www.G2Gconsulting.com

Government Bioscience Grant (GBG) Report
May 2016

	Title (Agency)	Opp. Number	Description	Deadline	Funding Level	Eligibility	Link
			BROAD AGENCY ANNOUNCEMENTS				
1	DoD Proof of Concept Commercialization Pilot Program	W911NF-16-R-0003	DoD is soliciting applications from current/recent grant awardees to receive mentoring and funding to accelerate the innovation of their funded research. The "I Corps @ DoD" program is designed to support the acceleration of innovation by providing PIs with training, mentorship, and funding. The purpose of this FOA is to accelerate the commercialization of basic research innovations.	9/15/16	Total Program Funding: \$500,000 Award Ceiling: \$70,000	Current or recent DoD grantees	http://www.grants.gov/web/grants/view-opportunity.html?oppId=283584
			WOUND HEALING				
2	NIH Non-healing Ulcerative Wounds in Aging (R01)	PA-16-230	This FOA invites applications that propose basic, clinical, or translational research on non-healing ulcerative wounds and their consequences in aging and in older persons. Research supported by this initiative should enhance knowledge of non-healing wounds and their consequences in older adults and provide evidence-based guidance in the diagnosis, evaluation, and/or treatment of non-healing wounds in older persons.	9/7/19	Contingent upon NIH funding	Unrestricted	http://grants.nih.gov/grants/guide/pa-files/PA-16-230.html# Section I. Funding
	R21 Companion Opportunity	PA-16-231	This companion opportunity is for exploratory R21 projects.	9/7/19	Award Ceiling: \$200,000	Unrestricted	http://grants.nih.gov/grants/guide/pa-files/PA-16-231.html

			MUSCKULOSKELETAL				
3	NIH Mechanisms Mediating Osteoarthritis in Aging (R21)	PA-16-240	This FOA invites applications on research employing genetically defined and/or modified mouse models, other animal models such as dogs and monkeys, or archived human joint tissues to explore the biological mechanisms underlying the initiation and progression of osteoarthritis.	9/7/19	Award Ceiling: \$275,000	Unrestricted	http://grants.nih.gov/grants/guide/pa-files/PA-16-240.html
	NIH Companion R01 Award	PA-16-239	This opportunity is the R01 companion FOA to the exploratory R21 announcement above.	9/7/19	Contingent upon NIH funding	Unrestricted	http://grants.nih.gov/grants/guide/pa-files/PA-16-239.html#_Section_I_Funding
4	DoD Duchenne Muscular Dystrophy Career Development Award	W81XW H-16-DMDRP-CDA	The CDA supports early-career investigators in conducting impactful Duchenne research under the mentorship of an experienced muscular dystrophy researcher as an opportunity to obtain the funding, mentoring, and experience necessary for productive, independent careers at the forefront of Duchenne research. Preliminary data are required.	10/19/16	Total Program Funding: \$880,000 Award Ceiling: \$275,000	Unrestricted	http://cdmrp.army.mil/funding/pa/16dmdrpdca_pa.pdf
	DoD Duchenne Muscular Dystrophy Investigator-Initiated Research Award	W81XW H-16-DMDRP-IIRA	The IIRA supports later stage translational research projects, including early-phase, proof-of-principle clinical trials and correlative studies to better inform the development of drugs, devices, and other interventions. Research projects may also include preclinical studies utilizing animal models, human subjects, or human anatomical substances.	10/19/16	Total Program Funding: \$1.92 m Award Ceiling: \$650,000	Unrestricted	http://cdmrp.army.mil/funding/pa/16dmdrpiira_pa.pdf

			NEURAL SYSTEMS				
5	DoD Neurofibromatosis Clinical Consortium Award	W81XW H-16-NFRP-CCA	This FOA is intended to support a major goal/product-driven Consortium of exceptional institutions and investigators that will accelerate the clinical translation of basic NF research and ultimately decrease the impact of the disease. The objectives of the Consortium shall be to conceive, design, develop, and conduct collaborative Phase I and II clinical evaluations of promising therapeutic agents for the management or treatment of NF1, NF2, and schwannomatosis.	Pre-application: 6/8/16 Full Application: 8/1/16	Total Program Funding: \$5 m	Unrestricted	http://cdmrp.army.mil/funding/pa/16nfrpcca_pa.pdf
	DoD Neurofibromatosis Clinical Trial Award	W81XW H-16-NFRP-CTA	Clinical trials supported by this FOA may be designed to evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance, and/or emerging approaches and technologies. Proposed projects may range from small proof-of-concept trials to demonstrate feasibility or inform the design of more advanced trials, through large-scale trials to determine efficacy in relevant patient populations.	Pre-application: 7/18/16 Full Application: 8/1/16	Total Program Funding: \$1.44 m	Unrestricted	http://cdmrp.army.mil/funding/pa/16nfrpcta_pa.pdf
	DoD Neurofibromatosis Investigator-Initiated Research Award	W81XW H-16-NFRP-IIRA	The NFRP Investigator-Initiated Research Award supports highly rigorous, high-impact research projects that have the potential to make an important contribution to NF research and/or patient care. Research projects may focus on any phase of research, excluding clinical trials.	Pre-application: 7/18/16 Full Application: 8/1/16	Total Program Funding: \$1.68 m	Unrestricted	http://cdmrp.army.mil/funding/pa/16nfrpiira_pa.pdf
	DoD Neurofibromatosis New Investigator Award	W81XW H-16-NFRP-NIA	The intent of the NFRP New Investigator Award is to support the development of promising independent investigators and/or the transition of established investigators from other research fields into a career in the field of NF research. Prior experience in NF research not required. PIs with a limited background in NF research are strongly encouraged to have a collaborator who is experienced in the NF field.	Pre-application: 7/18/16 Full Application: 8/1/16	Total Program Funding: \$2.88 m Award Ceiling: \$450,000	Unrestricted	http://cdmrp.army.mil/funding/pa/16nfrpnia_pa.pdf

DoD Tuberos Sclerosis Complex Exploration-Hypothesis Development Award	W81XW H-16-TSCRPEHDA	The EHDA supports the initial exploration of innovative, high-risk, high-gain, and potentially groundbreaking concepts in the TSC research field. The proposed research project should include a well-formulated, testable hypothesis based on strong scientific rationale and study design.	Pre-application: 7/1/16 Full Application: 7/18/16	Program Funding: \$1.6 m Award Ceiling: \$200,000	Unrestricted	http://cdmrp.army.mil/funding/pa/16tscrpehda_pa.pdf
DoD Tuberos Sclerosis Idea Development Award	W81XW H-16-TSCRPIDA	The IDA promotes ideas that have the potential to yield high-impact findings and new avenues of investigation. This award mechanism supports conceptually innovative research that could ultimately lead to critical discoveries in TSC research and/or improvements in patient care. Research projects should include a well-formulated, testable hypothesis based on strong preliminary data and scientific rationale.	Pre-application: 7/1/16 Full Application: 7/18/16	Program Funding: \$1.44 m Award Ceiling: \$450,000	Unrestricted	http://cdmrp.army.mil/funding/pa/16tscrpida_pa.pdf
DoD FY16 Tuberos Sclerosis Complex Synergistic Idea Development Award	W81XW H-16-TSCRPSIDA	The TSCRPS Synergistic Idea Development Award mechanism is being offered for the first time in FY16. The Synergistic Idea Development Award supports new or existing partnerships between two or three PIs who should utilize their complementary and synergistic perspectives to significantly accelerate advances in TSC research to support the TSCRPS vision to lessen the impact of TSC.	Pre-application: 7/1/16 Full Application: 7/18/16	Program Funding: \$1.2 m Award Ceiling: \$750,000	Unrestricted	http://cdmrp.army.mil/funding/pa/16tscrpsida_pa.pdf
DoD FY16 Tuberos Sclerosis Complex Pilot Clinical Trial Award	W81XW H-16-TSCRPPCTA	The PCTA mechanism supports exploratory studies involving limited human exposure that produce information on diagnostic or therapeutic effectiveness, safety, tolerability, or mechanisms of action. These studies should be aimed at obtaining preliminary data leading to the development of interventions with the potential to improve TSC outcomes.	Pre-application: 7/1/16 Full Application: 7/18/16	Program Funding: \$480,000 Award Ceiling: \$300,000	Unrestricted	http://cdmrp.army.mil/funding/pa/16tscrppcta_pa.pdf

	DoD Tuberos Sclerosis Complex Postdoctoral Development Award	W81XW H-16-TSCR-PDA	The Postdoctoral Development Award supports recent doctoral or medical graduates to conduct impactful research with the mentorship of an experienced TSC researcher. This opportunity allows for junior investigators to develop and investigate a TSC research project and further their intellectual development as a TSC researcher of the future.	Pre-application: 7/1/16 Full Application: 7/18/16	Total Program Funding: \$720,000 Award Ceiling: \$150,000	Unrestricted	http://cdmrp.army.mil/funding/pa/16tscrppda_pa.pdf
6	DoD Spinal Cord Injury Translational Award	W81XW H-16-SCIRP-TRA	The SCIRP TRA is intended to support translational research that will accelerate the movement of promising ideas in SCI research into clinical applications. Examples include demonstration studies of pharmaceuticals and medical devices in preclinical systems, and/or clinical research on therapeutics, devices, or practice using human tissues or resources.	Pre-application: 6/21/16 Full Application: 9/21/16	Program Funding: \$6 m Award Ceiling: \$1.25 m	Unrestricted	http://cdmrp.army.mil/funding/pa/16scirptra_pa.pdf
	DoD Spinal Cord Injury Qualitative Award	W81XW H-16-SCIRP-QRA	The intent of the Qualitative Research Award is to support qualitative research studies that will help researchers and clinicians better understand the experiences of individuals with SCI and thereby identify the most effective paths for adjusting to disability and/or improving overall quality of life, health, and functional status after SCI.	Pre-application: 6/21/16 Full Application: 9/21/16	Program Funding: \$3.2 m Award Ceiling: \$500,000	Unrestricted	http://cdmrp.army.mil/funding/pa/16scirpqrpa_pa.pdf
7	NIH From Association to Function in the Alzheimers Disease Post Genomics Era (R21)	RFA-AG-17-011	This FOA solicits early stage innovative and exploratory research focused on understanding the structure and function of proteins or protein complexes regulated by different AD genetic variants that have been identified to be associated with the sporadic and late onset Alzheimers.	9/27/16	Program Funding: \$1 m Award Ceiling: \$200,000	Unrestricted	http://grants.nih.gov/grants/guide/rfa-files/RFA-AG-17-011.html
	NIH R01 Companion Opportunity	RFA-AG-17-010	This is the R01 companion opportunity to the above.	9/27/16	Program Funding: \$4 m Award Ceiling: \$350,000	Unrestricted	http://grants.nih.gov/grants/guide/rfa-files/RFA-AG-17-010.html

	NIH Impact of Aging in Human Cell Models of Alzheimer's Disease (R01)	RFA-AG-17-009	The goal of this FOA is to establish the impact of aging on the expression and/or modulation of AD pathological processes and to assess age-related AD genotype-phenotype relationships in human cell models. Research incorporating different brain cell types to promote neural circuit maturation and complexity in such cell models is expected to better recapitulate and give greater insight into AD pathological processes.	Letters of Intent Due: 8/28/16 Applications Due: 9/28/16	Total Program Funding: \$2.25 m Award Ceiling: \$250,000	Unrestricted	http://grants.nih.gov/grants/guide/rfa-files/RFA-AG-17-009.html
			NEUROLOGICAL CANCER STUDIES				
8	NIH Neural Regulation of Cancer (R01)	PAR-16-245	The purpose of this FOA is to encourage collaborative, transdisciplinary research with both neuroscience and cancer elements to advance current understanding of the nervous system contribution to cancer.	6/27/19	Contingent upon NIH funding	Unrestricted	http://grants.nih.gov/grants/guide/pa-files/PAR-16-245.html
	NIH R21 Companion Opportunity	PAR-16-246	This FOA is the exploratory R21 companion opportunity to the above.	6/27/19	Award Ceiling: \$200,000	Unrestricted	http://grants.nih.gov/grants/guide/pa-files/PAR-16-246.html

			CANCER				
9	DoD Peer Reviewed Cancer Idea Award with Special Focus	W81XW H-16-PRCRP-IA	This FOA supports innovative, untested, high-risk/potentially high-reward concepts, theories, paradigms, and/or methods in cancer research that are relevant to Service members, their families, Veterans, and other military beneficiaries. The “Special Focus” of this award mechanism is on exposures, conditions, or circumstances that are unique to the military, disproportionately represented in a military beneficiary population, or may affect mission readiness.	Pre-application: 6/81/6 Application: 9/13/16	Total Program Funding: \$13.44 m Award Ceiling: \$400,000	Unrestricted	http://cdmrp.army.mil/funding/pa/16prcrpia_pa.pdf
10	NIH Metabolic Reprogramming to Improve Immunotherapy (R21)	PAR-16-229	The goal of this FOA is to encourage R21 exploratory/developmental grant applications to (a) generate a mechanistic understanding of the metabolic processes that support robust anti-tumor immune responses in vivo, (b) determine how the metabolic landscape of the tumor microenvironment affects immune effector functions, and (c) then use this information to manipulate (reprogram) the metabolic pathways used by the tumor, the immune response, or both to improve cancer immunotherapy.	9/7/19	Award Ceiling: \$200,000	Unrestricted	http://grants.nih.gov/grants/guide/pa-files/PAR-16-229.html
	NIH Metabolic Reprogramming to Improve Immunotherapy (R01)	PAR-16-228	This is an R01 companion opportunity to the above FOA.	9/7/19	Contingent upon NIH funding	Unrestricted	http://grants.nih.gov/grants/guide/pa-files/PAR-16-228.html
11	DoD Lung Cancer Concept Award	W81XW H-16-LCRP-CA	The Concept Award supports the exploration of a highly innovative new concept or untested theory that addresses an important problem relevant to lung cancer. The Concept Award is not intended to support an incremental progression of an already established research project but, instead, allows PIs the opportunity to pursue serendipitous observations.	Pre-application: 7/28/16 Application: 8/11/16	Program Funding: \$2.08 m Award Ceiling: \$100,000	Unrestricted	http://cdmrp.army.mil/funding/pa/16lcrpca_pa.pdf

12	DoD Prostate Cancer Physician Research Award	W81XW H-16- PCRP- PRA	This award emphasizes equally the quality of the proposed research project and the career development of the PI, which should prepare physicians for careers in basic, population science, translational, or clinical prostate cancer research. The inclusion of preliminary data relevant to prostate cancer and the proposed project is encouraged but not required.	Pre-application: 7/7/16 Application: 7/21/16	Program Funding: \$4.16 m Award Ceiling: \$520,000	Unrestricted	http://cdmrp.army.mil/funding/pa/16pcrppra_pa.pdf
	DoD Prostate Cancer Idea Development Award	W81XW H-16- PRCRP- IDA	The PCRP seeks applications from investigators from a spectrum of disciplines including, but not limited to, basic science, engineering, bioinformatics, population science, psycho-oncology, translational research, and clinical research.	Pre-application: 6/23/16 Application: 10/6/16	Program Funding: \$31.5 m Award Ceiling: \$1 m	Unrestricted	http://cdmrp.army.mil/funding/pa/16pcrpida_pa.pdf
	DoD Prostate Cancer Health Disparity Research Award	W81XW H-16- PCRP- HDRA	Studies proposed for this award mechanism are expected to improve the understanding of, and ultimately contribute to eliminating disparities in prostate cancer incidence, morbidity, mortality, and survivorship. Applicants for this award must explicitly state how the proposed research is related to an area of prostate cancer health disparity.	Pre-application: 6/9/16 Application: 8/25/16	Program Funding: \$5.76 m Award Ceiling: \$450,000	Unrestricted	http://cdmrp.army.mil/funding/pa/16pcrphdra_pa.pdf
	DoD Prostate Cancer Early Investigator Research Award	W81XW H-16- PCRP- EIRA	This FOA allows for young investigators to develop a research project, investigate a problem or question in prostate cancer research, and further their intellectual development as a prostate cancer researcher of the future. The PI must exhibit strong potential for, and commitment to, pursuing a career as an investigator at the forefront of prostate cancer research.	Pre-application: 7/7/16 Application: 7/21/16	Program Funding: \$5.96 m Award Ceiling: \$60,000	Unrestricted	http://cdmrp.army.mil/funding/pa/16pcrpeira_pa.pdf
	DoD Prostate Cancer Impact Award	W81XW H-16- PCRP-IA	The Impact Award is intended to support the full spectrum of research ideas from basic research to clinical trials. While the potential impact of the proposed research may be near-term or long-term, it must be significant and non-incremental. Applications must articulate the pathway to making a clinical impact for individuals with, or at risk for, prostate cancer, even if clinical impact is not an immediate outcome.	Pre-application: 6/9/16 Application: 8/25/16	Program Funding: \$17.6 m Award Ceiling: \$2 m	Unrestricted	http://cdmrp.army.mil/funding/pa/16pcrpia_pa.pdf

13	NIH Gene Fusion in Pediatric Sarcomas (R01)	PA-16-251	The goal of this FOA is to encourage the submission of research grant applications to investigate the molecular mechanisms by which oncogenic fusion genes and their gene products contribute to pediatric sarcoma initiation, progression, and metastasis.	5/7/19	Contingent upon NIH funding	Unrestricted	http://grants.nih.gov/grants/guide/pa-files/PA-16-251.html#_Section_I_Funding
	NIH R21 Companion Opportunity	PA-16-252	This FOA is the exploratory R21 companion opportunity to the above.	5/7/19	Award Ceiling: \$275,000		
14	NIH Program to Assess the Rigor and Reproducibility of Exosome-Derived Analytes for Cancer Detection (R21)	PAR-16-277	The purpose of this FOA is to encourage innovative research into the rigor and reproducibility of isolation and characterization of exosomes, other extracellular vesicles and their cargo for discovery of predictive biomarkers for risk assessment, detection, diagnosis and prognosis of early cancer. This FOA will promote research in both the isolation of exosomes as well as the computational analysis of the cargo carried in these vesicles.	6/13/19	Award Ceiling: \$200,000	Unrestricted	http://grants.nih.gov/grants/guide/pa-files/PAR-16-277.html
	NIH R01 Companion Opportunity	PAR-16-276	This is a R01 companion opportunity to the above.	6/13/19	Contingent upon NIH funding	Unrestricted	http://grants.nih.gov/grants/guide/pa-files/PAR-16-276.html
			GENOMIC CANCER STUDIES				
15	NIH Role of Mobile Genetic Elements in Cancer (R01)	PAR-16-227	This FOA invites research applications that specifically investigate mechanisms regulating the expression and activity of mobile genetic elements in the context of cell transformation and assess the impact of their mobilization on tumor heterogeneity, cancer evolution, and response to therapy.	9/7/19	Contingent upon NIH funding	Unrestricted	http://grants.nih.gov/grants/guide/pa-files/PAR-16-227.html
	(R21) Companion Opportunity	PAR0160226	This FOA is an exploratory companion opportunity to the above FOA.	9/7/19	Award Ceiling: \$200,000	Unrestricted	http://grants.nih.gov/grants/guide/pa-files/PAR-16-226.html

PHARMACEUTICALS							
16	NIH Serious Adverse Drug Reaction Research (R01)	PAR-16-275	The objective of this FOA is to encourage research projects addressing current gaps in our knowledge of serious ADRs. Potential areas of study include, but are not limited to, basic research into the immunologic, cellular, molecular, and toxicological mechanisms underlying serious ADRs, the identification of biomarkers and other population aspects of genetic susceptibility/pharmacogenomics and epidemiology of serious ADRs, and the development of therapies and interventions to treat and prevent serious ADRs.	9/7/19	Contingent upon NIH funding	Unrestricted	http://grants.nih.gov/grants/guide/pa-files/PAR-16-275.html#_Section_I_Funding
	NIH R21 Companion Opportunity	PAR-16-274	This FOA is an exploratory R21 companion opportunity to the above.	9/7/19	Award Ceiling: \$200,000	Unrestricted	http://grants.nih.gov/grants/guide/pa-files/PAR-16-274.html
17	NIH Partnerships for Structure-Based Design of Novel Immunogens for Vaccine Development (R01)	RFA-AI-16-047	The objective of this FOA is to solicit applications from multi-disciplinary teams for research projects that use 3-D structural information and novel computational methods to design new and improved vaccine immunogens.	10/3/16	Total Program Funding: \$6.3 m Number of Awards: 5-10	Unrestricted	http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-16-047.html
IMAGING							
18	NIH Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R01)	PAR-16-266	This FOA invites research grant applications from organizations/institutions that propose the development of novel radioligands for positron emission tomography (PET) or single photon emission computed tomography (SPECT) imaging in human brain, and that incorporate pilot or clinical feasibility evaluation in pre-clinical studies, model development, or clinical studies.	9/7/19	Contingent upon NIH funding	Unrestricted	http://grants.nih.gov/grants/guide/pa-files/PAR-16-266.html#_Section_II_Award_1

BIOMEDICAL ENGINEERING							
19	NIH Bioengineering Research Grants (BRG)(R01)	PAR-16-242	The purpose of this FOA is to encourage BRG applications that: 1) apply a multidisciplinary approach to the solution of a biomedical problem; and 2) integrate, optimize, validate, translate or otherwise accelerate the adoption of promising tools, methods and techniques for a specific research or clinical problem in basic, translational, or clinical science and practice. A list of research areas is available in the announcement.	5/7/19	Contingent upon NIH funding	Unrestricted	http://grants.nih.gov/grants/guide/pa-files/PAR-16-242.html#_Section_I_Funding
GULF WAR ILLNESS							
20	DoD Gulf War Illness Investigator-Initiated Focused Research Award	W81XW H-16-GWIRP-IIRFA	This FOA supports research to promote new ideas or continued development of applied research in GWI aimed at diagnosis or therapeutic advancement. Applications must articulate the pathway to making a clinical impact for Veterans with GWI even if a clinical impact is not an immediate outcome. All applications must focus on Veterans of the 1990-1991 Persian Gulf War affected by GWI.	Pre-application: 7/15/16 Application: 10/20/16	Program Funding: \$7.36 m Award Ceiling: \$200,000	Unrestricted	http://cdmrp.army.mil/funding/pa/16gwirpiifra_pa.pdf
	DoD Gulf War Illness Treatment Evaluation Award	W81XW H-16-GWIRP-TEA	This Award supports evaluation of a treatment or intervention in early phase or pilot clinical trials (Phase 0, I, or I/II) with the potential to have significant impact on the health and lives of Veterans with GWI. Health outcomes of interest should include improvements in overall functional status or in symptom complexes (e.g., cognitive function, musculoskeletal/pain symptoms, gastrointestinal symptoms, fatigue, respiratory problems, skin abnormalities, sleep difficulties and others) individually and/or as they may interact with each other.	Pre-application: 7/15/16 Application: 10/20/16 /20/16	Program Funding: \$4.48 m Award Ceiling: \$700,000	Unrestricted	http://cdmrp.army.mil/funding/pa/16gwirptea_pa.pdf

			DEPARTMENT OF DEFENSE: PEER-REVIEWED MEDICAL RESEARCH PROGRAMS				
21	DoD Peer Reviewed Medical Research Program Discovery Award	W81XW H-16-PRMRP-DA	The goal of this FOA from the Defense Health Program is to improve the health and well-being of all military service members, veterans, and beneficiaries. The PRMRP seeks to address at least one of the FY16 topic areas with original ideas that foster new directions along the entire spectrum of research and clinical care. Topic areas are listed in the program announcement.	Pre-application: 7/7/16 Full Application: 7/21/16	Total Program Funding: \$14.4 m Award Ceiling: \$200,000	Unrestricted	http://cdmrp.army.mil/funding/pa/16prmrpdapa.pdf
22	DoD Peer Reviewed Medical Technology/Therapeutic Development Award	W81XW H-16-PRMRP-TTDA	This FOA is a product-driven award mechanism intended to provide support for the translation of promising preclinical findings into products for clinical applications, including prevention, detection, diagnosis, treatment, or quality of life, in at least one of the Congressionally directed FY16 PRMRP Topic Areas. Products in development should be responsive to the healthcare needs of military Service members, Veterans, and/or beneficiaries.	Pre-application: 6/23/16 Full Application: 10/19/16	Total Program Funding: \$45 m Award Ceiling: \$3 m	Unrestricted	http://cdmrp.army.mil/funding/pa/16prmrpttda_pa.pdf
23	DoD Peer Reviewed Medical Focused Program Award	W81XW H-16-PRMRP-FPA	This FOA is intended to optimize research and accelerate the solution for a critical question related to at least one of the Congressionally directed FY16 PRMRP Topic Areas through a synergistic, multidisciplinary research program.	Pre-application: June 29, 2016 Full Application: 10/26/16	Total Program Funding: \$50 m Award Ceiling: \$10 m	Unrestricted	http://cdmrp.army.mil/funding/pa/16prmrpttda_pa.pdf
24	DoD Peer Reviewed Medical Investigator-Initiated Research Award	W81XW H-16-PRMRP-IIA	This FOA is intended to support studies that will make an important contribution toward research and/or patient care for a disease or condition related to at least one of the Congressionally directed FY16 PRMRP Topic Areas. The rationale for a research idea may be derived from a laboratory discovery, population-based studies, a clinician's first-hand knowledge of patients, or anecdotal data. Applications must include relevant data that support the rationale for the proposed study.	Pre-application Due: 6/23/16 Full Application Due: 10/19/16	Total Program Funding: \$91.3 m Award Ceiling: \$1.2 m	Unrestricted	http://cdmrp.army.mil/funding/pa/16prmrpiira_pa.pdf

25	DoD Peer Reviewed Medical Clinical Trial Award	W81XW H-16-PRMRP-CTA	This FOA supports the rapid implementation of clinical trials with the potential to have a significant impact on a disease or condition addressed in at least one of the Congressionally directed FY16 PRMRP Topic Areas. Clinical trials may be designed to evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance, and/or emerging approaches and technologies. Proposed projects may range from small proof-of-concept trials to demonstrate feasibility or inform the design of more advanced trials, through large-scale trials to determine efficacy in relevant patient populations.	Pre-application: 6/29/16 Full Application: 10/26/16	Total Program Funding: \$48 m	Unrestricted	http://cdmrp.army.mil/funding/pa/16prmrpcta_pa.pdf
			PRESCRIPTION DRUG ABUSE				
26	NIH Prescription Drug Abuse (R01)	PA-16-233	This FOA encourages applicants to develop innovative research applications on prescription drug abuse, including research to examine the factors contributing to prescription drug abuse; to characterize the adverse medical, mental health and social consequences associated with prescription drug abuse; and to develop effective prevention and service delivery approaches and behavioral and pharmacological treatments.	5/7/19	Contingent upon NIH funding	Unrestricted	http://grants.nih.gov/grants/guide/pa-files/PA-16-233.html#_Section_I_Funding
	NIH R21 Companion Opportunity	PA-16-232	This is an exploratory R21 companion opportunity to the above. Each announcement contains a detailed list of research areas of interest to NIH.	5/7/19	Award Ceiling: \$200,000	Unrestricted	http://grants.nih.gov/grants/guide/pa-files/PA-16-232.html

			INFECTIOUS DISEASES				
27	NIH Novel Approaches to Understanding, Preventing, and Treating Lyme Disease and Tick-borne Coinfections (R01)	PA-16-243	The purpose of this FOA is to support research that will contribute to the overall understanding of Lyme disease and co-infections transmitted by <i>Ixodes</i> ticks. This research opportunity encourages studies that address diverse scientific areas such as 1) pathogenesis, 2) host response, 3) disease transmission, 4) vector biology and natural history, 5) vaccines, 6) diagnostics, and 7) therapeutics.	9/7/19	Contingent upon NIH funding	Unrestricted	http://grants.nih.gov/grants/guide/pa-files/PA-16-243.html
	NIH Companion R21 Opportunity	PA-16-244	This is an exploratory R21 companion opportunity to the above FOA.	9/7/19	\$200,000	Unrestricted	http://grants.nih.gov/grants/guide/pa-files/PA-16-244.html
28	NIH Mechanisms of Mycobacterial-Induced Immunity in HIV-Infected and Uninfected Individuals to Inform Tuberculosis Vaccine Design (R01)	PAR-16-254	This FOA encourages innovative, high risk, high impact research to investigate the innate and/or adaptive immune responses induced by mycobacterial infections, Bacillus Calmette-Gurin vaccine and/or candidate Mycobacterium tuberculosis vaccines. This research is expected to provide data to advance new hypotheses on immune mechanisms that contribute to the advancement of new tuberculosis vaccines, including in populations also infected with HIV.	9/6/18	Contingent upon NIH funding	Unrestricted	http://grants.nih.gov/grants/guide/pa-files/PAR-16-254.html
	NIH R21 Companion Opportunity	PAR-15-360	This FOA is a companion R21 opportunity to the above.	9/6/18	Award Ceiling: \$200,000	Unrestricted	http://grants.nih.gov/grants/guide/pa-files/PAR-15-360.html#_Section_II_Award_1

29	NIH SBIR Phase II Clinical Trial Implementation Cooperative Agreement (U44)	PAR-16-271	This FOA invites SBIR grant applications that propose to implement investigator-initiated clinical trials related to the research mission of the National Institute of Allergy and Infectious Diseases. This program provides support for hypothesis-driven, milestone-driven clinical trials.	5/3/19	Award Ceiling: \$1 m for Phase II	Unrestricted	http://grants.nih.gov/grants/guide/pa-files/PAR-16-271.html#_Section_I_Funding
	NIH U01 Companion Opportunity	PAR-16-270	The U01 companion opportunity encourages mechanistic studies associated with high-risk clinical trials.	5/3/19	Contingent upon NIH funding	Unrestricted	http://grants.nih.gov/grants/guide/pa-files/PAR-16-270.html
	NIAID Clinical Trail Implementation Grant (R01)	PAR-16-269	This companion (FOA) encourages applications for implementation of investigator-initiated, non-high-risk clinical trials.	5/3/19	Contingent upon NIH funding	Unrestricted	http://grants.nih.gov/grants/guide/pa-files/PAR-16-269.html